LEH Pharma   Report issue

For profit Phase 3
Founded: London United Kingdom (2011)
Status: No NME R&D (2011)

Organization Overview

First Clinical Trial
2018
NCT03489941
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

EyeMax, LLC

Active Ingredients

Drugs in Phase 3 Trials (2)

em-100 (1 trial)

ketotifen (zaditor) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Conjunctivitis (Phase 3)

Conjunctivitis, Allergic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 1
  • # of Trial APIs: 2